tocilizumab   

GtoPdb Ligand ID: 6881

Synonyms: Actemra® | R-1569 | RG-1569 | RHPM-1 | RoActemra®
tocilizumab is an approved drug (FDA (2010), EMA (2009))
Compound class: Antibody
Comment: Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action [6] that is approved for chronic autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808).

In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection in some patients and which leads to potentially life-threatening lung damage.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tocilizumab

Bioactivity Comments
Unfortunately, we have been unable to find publicly available data providing a binding affinity for this antibody at its molecular target.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin-6 receptor Hs Antibody Binding 8.6 pKd -
pKd 8.6 (Kd 2.54x10-9 M)